Anzeige
Mehr »
Login
Mittwoch, 28.02.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
Feuerwerk fürs Depot: Rohstoff-Geheimtipp! Startet JETZT der Kursturbo?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PJ5B | ISIN: KYG4672N1198 | Ticker-Symbol: H7T2
Frankfurt
28.02.24
12:56 Uhr
2,900 Euro
+0,140
+5,07 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
HUTCHMED CHINA LIMITED Chart 1 Jahr
5-Tage-Chart
HUTCHMED CHINA LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
2,8803,40013:39
2,9203,34013:18

Aktuelle News zur HUTCHMED Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:29HUTCHMED Turns To Profit In FY23, Revenue Surges; Stock Up In Pre-market1
12:48Hutchison China MediTech reports FY results1
12:47HUTCHMED Ltd - 6-K, Report of foreign issuer1
12:41HUTCHMED Ltd - 20-F, Annual and transition report of foreign private issuers-
12:36HUTCHMED (China) Limited: HUTCHMED Reports 2023 Full Year Results and Provides Business Updates59Revenue grew 97% (102% CER) to US$838 million, with net income of US$101 million First U.S. FDA approval of our self-developed medicine, FRUZAQLA (fruquintinib) Sovleplenib for ITP accepted for...
► Artikel lesen
12:30HUTCHMED (00013): HUTCHMED REPORTS 2023 FULL YEAR RESULTS AND PROVIDES BUSINESS UPDATES1
11:30Hutchmed China Ltd - 2023 Full Year Results and Business Updates-
DiHutchison China MediTech FY 2023 Earnings Preview1
07.02.HUTCHMED Ltd - 6-K, Report of foreign issuer-
07.02.Hutchmed hails fruquintinib trial results for gastric cancer treatment1
07.02.Hutchmed China Ltd - Presentation of Phase III Data on Fruquintinib-
07.02.listed HUTCHMED jumps on positive progress of gastric cancer drug1
07.02.HUTCHMED (China) Limited: HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session114HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:?HCM; HKEX:?13) today announces that data from FRUTIGA, HUTCHMED's...
► Artikel lesen
07.02.HUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED HIGHLIGHTS PRESENTATION OF PHASE III DATA ON FRUQUINTINIB IN SECOND-LINE GASTRIC CANCER AT ASCO PLENARY ...-
05.02.Inmagene to secure licence for two HUTCHMED drug candidates1
02.02.Hutchmed grants exclusive license to Inmagene for two drug candidates1
02.02.Hutchmed partner Inmagene exercises options over two drug candidates1
02.02.Hutchmed says Inmagene exercises option to licence drug candidates1
02.02.HUTCHMED (China) Limited: HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership224HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announced that, Inmagene Biopharmaceuticals...
► Artikel lesen
02.02.HUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED ANNOUNCES THAT INMAGENE EXERCISES OPTION TO LICENSE TWO DRUG CANDIDATES AS PART OF STRATEGIC PARTNERSHIP1
Seite:  Weiter >>
114 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1